Lexeo Therapeutics Plans Conference Presentations on Gene Therapy Programs

Lexeo says its AHA presentations will highlight its cardiovascular gene therapy pipeline. It also plans to present LX2006 data at ICAR, describing cardiac and neurologic benefits through 36 months.